Informations:
Erreur:
ID
12909
Description
Risk-Adapted Therapy of Acute Myeloid Leukemia of Adults (18-60 Years) According to the Cytogenetic Result; ODM derived from: https://clinicaltrials.gov/show/NCT00146120
Lien
https://clinicaltrials.gov/show/NCT00146120
Mots-clés
Versions (1)
- 06/01/2016 06/01/2016 -
Détendeur de droits
CC BY-NC 3.0
Téléchargé le
6 janvier 2016
DOI
Pour une demande vous connecter.
Licence
Creative Commons BY-NC 3.0
Modèle Commentaires :
Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.
Groupe Item commentaires pour :
Item commentaires pour :
Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.
Eligibility Acute Myeloid Leukemia NCT00146120
Eligibility Acute Myeloid Leukemia NCT00146120
- StudyEvent: Eligibility
Similar models
Eligibility Acute Myeloid Leukemia NCT00146120
- StudyEvent: Eligibility
Name
Type
Description | Question | Decode (Coded Value)
Type de données
Alias
patients with aml, de novo or secondary after myelodysplasy, or with therapy-induced aml after healed primary malignom; or refractory anemia with excess of blasts in transformation (raeb-t); the diagnosis must be confirmed morphological, cytochemical and with immunological phenotyping
Item
patients with aml, de novo or secondary after myelodysplasy, or with therapy-induced aml after healed primary malignom; or refractory anemia with excess of blasts in transformation (raeb-t); the diagnosis must be confirmed morphological, cytochemical and with immunological phenotyping
boolean
C0023467 (UMLS CUI [1])
C0002893 (UMLS CUI [2])
C0002893 (UMLS CUI [2])
cytogenetical tests must be performed for each patient
Item
cytogenetical tests must be performed for each patient
boolean
C0010802 (UMLS CUI [1])
age: 16 - 60 years
Item
age: 16 - 60 years
boolean
C0001779 (UMLS CUI [1])
all patients have to be informed about the character of the study. written informed consent of each patient at study entry.
Item
all patients have to be informed about the character of the study. written informed consent of each patient at study entry.
boolean
C0021430 (UMLS CUI [1])
organic insufficiency: insufficiency of the kidneys (crea > 1.5 x upper normal serum level), or insufficiency of the liver (bilirubin, sgot or ap > 2 x upper normal serum level) uncaused by the aml; severe obstruction or restrictive ventilation disorder, heart failure with a ejection fraction < 0.5
Item
organic insufficiency: insufficiency of the kidneys (crea > 1.5 x upper normal serum level), or insufficiency of the liver (bilirubin, sgot or ap > 2 x upper normal serum level) uncaused by the aml; severe obstruction or restrictive ventilation disorder, heart failure with a ejection fraction < 0.5
boolean
C0201976 (UMLS CUI [1])
C1278039 (UMLS CUI [2])
C0035204 (UMLS CUI [3])
C0232174 (UMLS CUI [4])
C1278039 (UMLS CUI [2])
C0035204 (UMLS CUI [3])
C0232174 (UMLS CUI [4])
secondary malignom
Item
secondary malignom
boolean
C0006826 (UMLS CUI [1])
other severe diseases
Item
other severe diseases
boolean
C0009488 (UMLS CUI [1])
pregnancy
Item
pregnancy
boolean
C0032961 (UMLS CUI [1])
participation in an concurrent clinical study
Item
participation in an concurrent clinical study
boolean
C2348568 (UMLS CUI [1])